NCI-H157人非小细胞肺腺癌细胞(STR鉴定正确)

价 格:¥3000

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1412

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameNCI-H157
SynonymsNCl-H157; NCI H157; H157; H-157; NCI-157; NCIH157DM; H157DM
AccessionBTCC-1412
Resource Identification InitiativeTo cite this cell line use: NCI-H157
CommentsProblematic cell line: Contaminated. NCI-H157 and NCI-H1264 have been shown to be identical.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00412.
Doubling time: 53 hours (Note=In RPMI 1640 + 10% FBS), 90 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 20.8 hours (PubMed=29681454).
Omics: Genomics; Whole exome sequencing.
Omics: Proteomics.
Omics: Proteomics; Expression; Reverse-phase protein array.
Omics: Transcriptomics; Microarray.
Omics: Transcriptomics; miRNA profiling; Microarray.
Omics: Variations; Array-based CGH.
Omics: Variations; SNP array analysis.
Sequence variations
  • Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Homozygous (PubMed=30038707; DepMap=ACH-000921).
  • Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; DepMap=ACH-000921).
  • Mutation; HGNC; HGNC:11100; SMARCA4; Simple; p.Thr58Profs*36 (c.171del); Zygosity=Homozygous (DepMap=ACH-000921).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Leu35Phefs*8 (c.102_103insT) (c.103_104insT); Zygosity=Heterozygous (PubMed=10536175; PubMed=20557307; DepMap=ACH-000921).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Heterozygous (PubMed=1311061; PubMed=10536175; PubMed=20557307; DepMap=ACH-000921).
DiseaseLung squamous cell carcinoma (NCIt: C3493)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:


CVCL_VD88 (H157R)CVCL_E3I3 (HyCyte NCI-H157-Luc)
Originate from same individualCVCL_3970 ! NCI-H1264
Sex of cellMale
Age at sampling59Y
CategoryCancer cell line
STR profileSource(s): ATCC=CRL-5802; CCRID=1101HUM-PUMC000113; CLS=300387

Markers:
AmelogeninX
CSF1PO12
D2S133821,22
D3S135817,18
D5S81810,13
D6S104317,24
D7S82012
D8S117914,16
D12S39120
D13S31712
D16S53912,13
D18S5113,15
D19S43311,13
D21S1132
FGA22,23
Penta D2.2
Penta E7
TH017,9
TPOX6,12
vWA15

Run an STR similarity search on this cell line
Web pagesInfo; ATCC; -; https://www.atcc.org/en/support/technical-support/faqs/cross-contamination-of-atcc-crl-5802-and-atcc-crl-5860
Info; ATCC; -; https://www.atcc.org/en/support/technical-support/faqs/misidentified-cell-lines-atcc-crl-5802-and-atcc-crl-5860
Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
Publications

PubMed=6270685; DOI=10.1073/pnas.78.7.4591; PMCID=PMC319839
Cuttitta F., Rosen S.T., Gazdar A.F., Minna J.D.
Monoclonal antibodies that demonstrate specificity for several types of human lung cancer.
Proc. Natl. Acad. Sci. U.S.A. 78:4591-4595(1981)

PubMed=6272398; DOI=10.1126/science.6272398
Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.
High levels of intracellular bombesin characterize human small-cell lung carcinoma.
Science 214:1246-1248(1981)

PubMed=6148444; DOI=10.1093/jnci/73.4.801
Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H. Jr., Mitchell J.B.
Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.
J. Natl. Cancer Inst. 73:801-807(1984)

PubMed=6713399
Rosen S.T., Mulshine J.L., Cuttitta F., Fedorko J., Carney D.N., Gazdar A.F., Minna J.D.
Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies.
Cancer Res. 44:2052-2061(1984)

PubMed=3940644
Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
Cancer Res. 46:798-806(1986)

PubMed=1311061
Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D., Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Oncogene 7:171-180(1992)

PubMed=1563005
Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.
Neuromedin B is present in lung cancer cell lines.
Cancer Res. 52:2732s-2736s(1992)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=8626706; DOI=10.1074/jbc.271.19.11477
Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.
Insulin-like growth factor expression in human cancer cell lines.
J. Biol. Chem. 271:11477-11483(1996)

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. Suppl. 24:32-91(1996)

PubMed=9649128; DOI=10.1038/bjc.1998.361; PMCID=PMC2150402
Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.
Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.
Br. J. Cancer 77:2162-2170(1998)

PubMed=10536175; DOI=10.3892/ijo.15.5.927
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Int. J. Oncol. 15:927-934(1999)

PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293
Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.
Mutation and expression of the DCC gene in human lung cancer.
Neoplasia 2:300-305(2000)

PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0
Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.
Cancer Genet. Cytogenet. 125:87-99(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12820372
Bergqvist M., Brattstrom D., Gullbo J., Hesselius P., Brodin O., Wagenius G.
p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer.
Anticancer Res. 23:1207-1212(2003)

PubMed=16187286; DOI=10.1002/ijc.21491
Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D., Gazdar A.F., Lam S., MacAulay C., Lam W.L.
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.
Int. J. Cancer 118:1556-1564(2006)

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)

PubMed=20624269; DOI=10.1186/1756-9966-29-75; PMCID=PMC2907339
Du L.-Q., Schageman J.J., Irnov I., Girard L., Hammond S.M., Minna J.D., Gazdar A.F., Pertsemlidis A.
MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.
J. Exp. Clin. Cancer Res. 29:75.1-75.12(2010)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J.S., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)

PubMed=23381221; DOI=10.3892/or.2013.2266; PMCID=PMC3621652
Suzuki M., Shiraishi K., Eguchi A., Ikeda K., Mori T., Yoshimoto K., Ohba Y., Yamada T., Ito T., Baba Y., Baba H.
Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer.
Oncol. Rep. 29:1308-1314(2013)

PubMed=25120651; DOI=10.3892/ol.2014.2234; PMCID=PMC4114630
Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K., Shibata H., Ito T., Baba Y., Baba H.
Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.
Oncol. Lett. 8:1025-1030(2014)

PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003
Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C., Daub H.
Comparative proteome analysis across non-small cell lung cancer cell lines.
J. Proteomics 130:1-10(2016)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028; PMCID=PMC5935540
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)

PubMed=30038707; DOI=10.18632/oncotarget.25642; PMCID=PMC6049873
Du L.-Q., Zhao Z.-Z., Suraokar M.B., Shelton S.S., Ma X.-Y., Hsiao T.-H., Minna J.D., Wistuba I.I., Pertsemlidis A.
LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.
Oncotarget 9:29601-29618(2018)

PubMed=31803961; DOI=10.1002/jcb.29564; PMCID=PMC7496084
Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
J. Cell. Biochem. 121:3986-3999(2020)

PubMed=38180245; DOI=10.1158/1078-0432.CCR-23-2360; PMCID=PMC11061608
Ng J., Cai L., Girard L., Prall O.W.J., Rajan N.S., Khoo C., Batrouney A., Byrne D.J., Boyd D.K., Kersbergen A.J., Christie M., Minna J.D., Burr M.L., Sutherland K.D.
Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as SMARCA4-deficient malignancies.
Clin. Cancer Res. 30:1846-1858(2024)

Cross-references
Cell line collections (Providers)ATCC; CRL-5802 - Discontinued
CLS; 300387
KCB; KCB 200814YJ
KCLB; 90157 - Discontinued
Cell line databases/resourcesCLO; CLO_0037032
MCCL; MCC:0000360
cancercelllines; CVCL_0463
CCRID; 1101HUM-PUMC000113
DepMap; ACH-000921
IGRhCellID; H157GEO
LINCS_LDP; LCL-1596
Anatomy/cell type resourcesBTO; BTO_0002283
Biological sample resourcesBioSample; SAMN03151855
BioSample; SAMN03471738
Chemistry resourcesChEMBL-Cells; CHEMBL3307706
ChEMBL-Targets; CHEMBL614783
PubChem_Cell_line; CVCL_0463
Encyclopedic resourcesWikidata; Q54907822
Experimental variables resourcesEFO; EFO_0003118

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部